Skip to main content

Table 3 Clinicopathological features of patient and healthy controls in the present study

From: Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma

  Plasm methylome Tissue qMSP Plasm BSP
  HC1 CHB2 LC3 HCC4 NSCLC5 HC1 LC3 HCC4 HC1 CHB2 LC3 HCC4
Cases 31 30 27 29 26 10 29 33 37 36 40 47
Gender             
Male 28 (90.3%) 27 (90.0%) 24 (88.9%) 26 (89.7%) 23 (88.5%) 6 (60%) 25 (86.2%) 27 (84.9%) 30 (81.1%) 28 (77.6%) 33 (78.8%) 39 (83.0%)
Female 3 (9.7%) 3 (10.0%) 3 (11.1%) 3 (10.3%) 3 (11.5%) 4 (40%) 4 (13.8%) 6 (15.1%) 7 (18.9%) 8 (22.2%) 7 (21.2%) 8 (17.0%)
Age 50.3 ± 8.6 50.7 ± 7.6 50.8 ± 9.6 55.8 ± 8.5 52.4 ± 9.6 42.2 ± 6.53 46.9 ± 9.2 50.3 ± 9.1 53.32 ± 5.3 52.53 ± 4.7 48.89 ± 10.7 54.29 ± 8.3
HBV infection             
Yes 0 (0%) 30 (100%) 27 (100%) 29 (100%) 0 (0%) 0 (0%) 30 (100%) 33 (100%) 0 (0%) 36 (100%) 40 (100%) 47 (100%)
No 31(100%) 0 (0%) 0 (0%) 0 (0%) 29 (100%) 10(100%) 0 (0%) 0 (0%) 37 (100%) 0 (0%) 0 (0%) 0 (0%)
Differentiation             
Poor   / / 11 (37.9%) 12 (46.2%) / / 15 (45.5%) / / / 22 (46.8%)
Moderate   / / 10 (34.5%) 8 (30.7%) / / 13 (39.4) / / / 15 (31.9%)
High   / / 8(27.6%) 6 (23.1%) / / 5 (15.1%) / / / 10 (21.3%)
Tumor stage             
I/II   / / 14 (48.3%) 10 (38.5%) / / 13 (39.4%) / / / 12 (25.5%)
III/IV   / / 15 (51.7) 16 (61.5%) / / 20 (60.6%) / / / 35 (74.5%)
Tumor size             
≤3cm   / / 16 (55.2%) / / / 11 (33.3%) / / / 16 (34.1%)
>3cm   / / 13 (44.8%) / / / 22 (66.7%) / / / 31 (65.9%)